A detailed history of Quest Partners LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 19,520 shares of PCRX stock, worth $498,931. This represents 0.05% of its overall portfolio holdings.

Number of Shares
19,520
Previous 13,493 44.67%
Holding current value
$498,931
Previous $254 Million 90.82%
% of portfolio
0.05%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$18.33 - $27.25 $110,474 - $164,235
6,027 Added 44.67%
19,520 $485 Million
Q4 2024

Feb 07, 2025

BUY
$15.3 - $20.33 $62,469 - $83,007
4,083 Added 43.39%
13,493 $254 Million
Q3 2024

Nov 07, 2024

BUY
$11.7 - $28.46 $63,753 - $155,078
5,449 Added 137.57%
9,410 $142 Million
Q2 2024

Aug 06, 2024

BUY
$25.5 - $31.51 $101,005 - $124,811
3,961 New
3,961 $113 Million
Q4 2023

Feb 09, 2024

BUY
$26.32 - $34.31 $97,673 - $127,324
3,711 New
3,711 $125 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.17B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.